These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 17200492

  • 1. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study.
    Murata M, Hasegawa K, Kanazawa I, Japan Zonisamide on PD Study Group.
    Neurology; 2007 Jan 02; 68(1):45-50. PubMed ID: 17200492
    [Abstract] [Full Text] [Related]

  • 2. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Parkinson Study Group.
    Arch Neurol; 2005 Feb 02; 62(2):241-8. PubMed ID: 15710852
    [Abstract] [Full Text] [Related]

  • 3. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease.
    Storch A, Jost WH, Vieregge P, Spiegel J, Greulich W, Durner J, Müller T, Kupsch A, Henningsen H, Oertel WH, Fuchs G, Kuhn W, Niklowitz P, Koch R, Herting B, Reichmann H, German Coenzyme Q(10) Study Group.
    Arch Neurol; 2007 Jul 02; 64(7):938-44. PubMed ID: 17502459
    [Abstract] [Full Text] [Related]

  • 4. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.
    Goetz CG, Damier P, Hicking C, Laska E, Müller T, Olanow CW, Rascol O, Russ H.
    Mov Disord; 2007 Jan 15; 22(2):179-86. PubMed ID: 17094088
    [Abstract] [Full Text] [Related]

  • 5. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH, Klasser M, Reichmann H.
    Fortschr Neurol Psychiatr; 2008 Oct 15; 76(10):594-9. PubMed ID: 18833504
    [Abstract] [Full Text] [Related]

  • 6. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, Alexander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O'Connell C, Ross T, Richard K, Watts A, Parkinson Study Group.
    Arch Neurol; 2004 Jul 15; 61(7):1044-53. PubMed ID: 15262734
    [Abstract] [Full Text] [Related]

  • 7. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients.
    Stern MB, Marek KL, Friedman J, Hauser RA, LeWitt PA, Tarsy D, Olanow CW.
    Mov Disord; 2004 Aug 15; 19(8):916-23. PubMed ID: 15300656
    [Abstract] [Full Text] [Related]

  • 8. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI.
    Int J Clin Pract; 2009 Apr 15; 63(4):613-23. PubMed ID: 19222614
    [Abstract] [Full Text] [Related]

  • 9. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease.
    Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G.
    Mov Disord; 2005 Aug 15; 20(8):958-63. PubMed ID: 15800937
    [Abstract] [Full Text] [Related]

  • 10. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures.
    Brodie MJ, Duncan R, Vespignani H, Solyom A, Bitenskyy V, Lucas C.
    Epilepsia; 2005 Jan 15; 46(1):31-41. PubMed ID: 15660766
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.
    Ziegler M, Castro-Caldas A, Del Signore S, Rascol O.
    Mov Disord; 2003 Apr 15; 18(4):418-25. PubMed ID: 12671949
    [Abstract] [Full Text] [Related]

  • 12. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).
    LeWitt PA, Guttman M, Tetrud JW, Tuite PJ, Mori A, Chaikin P, Sussman NM, 6002-US-005 Study Group.
    Ann Neurol; 2008 Mar 15; 63(3):295-302. PubMed ID: 18306243
    [Abstract] [Full Text] [Related]

  • 13. Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures.
    Sackellares JC, Ramsay RE, Wilder BJ, Browne TR, Shellenberger MK.
    Epilepsia; 2004 Jun 15; 45(6):610-7. PubMed ID: 15144425
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study.
    Suwantamee J, Nidhinandana S, Srisuwananukorn S, Laptikultham S, Pisarnpong A, Chankrachang S, Bundhukul A.
    J Med Assoc Thai; 2004 Nov 15; 87(11):1293-300. PubMed ID: 15825702
    [Abstract] [Full Text] [Related]

  • 15. Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study.
    Mizuno Y, Abe T, Hasegawa K, Kuno S, Kondo T, Yamamoto M, Nakashima M, Kanazawa I, STRONG Study Group.
    Mov Disord; 2007 Oct 15; 22(13):1860-5. PubMed ID: 17618525
    [Abstract] [Full Text] [Related]

  • 16. Zonisamide improves wearing-off in Parkinson's disease: A randomized, double-blind study.
    Murata M, Hasegawa K, Kanazawa I, Fukasaka J, Kochi K, Shimazu R, Japan Zonisamide on PD Study Group.
    Mov Disord; 2015 Sep 15; 30(10):1343-50. PubMed ID: 26094993
    [Abstract] [Full Text] [Related]

  • 17. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease.
    Stacy M, Silver D, Mendis T, Sutton J, Mori A, Chaikin P, Sussman NM.
    Neurology; 2008 Jun 03; 70(23):2233-40. PubMed ID: 18519872
    [Abstract] [Full Text] [Related]

  • 18. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
    da Silva-Júnior FP, Braga-Neto P, Sueli Monte F, de Bruin VM.
    Parkinsonism Relat Disord; 2005 Nov 03; 11(7):449-52. PubMed ID: 16154788
    [Abstract] [Full Text] [Related]

  • 19. Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study.
    Mizuno Y, Hasegawa K, Kondo T, Kuno S, Yamamoto M, Japanese Istradefylline Study Group.
    Mov Disord; 2010 Jul 30; 25(10):1437-43. PubMed ID: 20629136
    [Abstract] [Full Text] [Related]

  • 20. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.
    Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, Elmer LW, Truong DD, Earl NL, EASE-PD Adjunct Study Investigators.
    Neurology; 2007 Apr 03; 68(14):1108-15. PubMed ID: 17404192
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.